S&P 500 (NYSE:SPY) component PerkinElmer, Inc. (NYSE:PKI) will unveil its latest earnings on Thursday, August 4, 2011. PerkinElmer, Inc. provides technology, services and solutions to the environmental monitoring, diagnostics, academic research and safety security markets.
PerkinElmer, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for profit of 40 cents per share, a rise of 5.3% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 39 cents. For the year, analysts are projecting net income of $1.67 per share, a rise of 25.6% from last year.
Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 4 cents, reporting profit of 34 cents per share against a mean estimate of net income of 30 cents per share.
Wall St. Revenue Expectations: On average, analysts predict $477.6 million in revenue this quarter, a decline of 4.1% from the year ago quarter. Analysts are forecasting total revenue of $1.93 billion for the year, a rise of 13.5% from last year’s revenue of $1.7 billion.
Analyst Ratings: Analysts are bullish on PerkinElmer as four analysts rate it as a buy, none rate it as a sell and four rate it as a hold.
Revenue has fallen for the past three quarters. In first quarter, revenue declined 3.7% to $447.9 million while the figure fell 7.7% in fourth quarter of the last fiscal year from the year earlier and 4.1% in the third quarter of the last fiscal year.
The decrease in profit in the first quarter comes after net income rose in the previous quarter. In the first quarter, net income fell 3.6% to $23.5 million. In the fourth quarter of the last fiscal year, net income rose more than sevenfold.
Competitors to Watch: Thermo Fisher Scientific Inc. (NYSE:TMO), Waters Corporation (NYSE:WAT), Beckman Coulter, Inc. (NYSE:BEC), Bruker Corporation (NASDAQ:BRKR), Harvard Bioscience, Inc. (NASDAQ:HBIO), Agilent Technologies Inc. (NYSE:A), Caliper Life Sciences Inc. (NASDAQ:CALP), Becton, Dickinson and Co. (NYSE:BDX), Bio-Rad Laboratories, Inc. (NYSE:BIO), and Sequenom, Inc. (NASDAQ:SQNM).
Stock Price Performance: During May 4, 2011 to July 29, 2011, the stock price had fallen $3.46 (-12.4%) from $27.92 to $24.46. It saw one of its worst periods between August 6, 2010 and August 16, 2010 when shares fell for seven-straight days, falling 4.2% (-93 cents) over that span. The stock price saw one of its best stretches over the last year between December 6, 2010 and December 14, 2010 when shares rose for seven-straight days, rising 5.2% (+$1.25) over that span. Shares are down $1.15 (-4.5%) year to date.
(Source: Xignite Financials)